Dexmedetomidine Supplemented Analgesia in Patients at High-risk of Obstructive Sleep Apnea
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Obstructive sleep apnea (OSA) is a common sleep disturbance that can cause intermittent
hypoxia, hypercapnia, and sleep structure disorders. The presence of OSA is associated with
worse outcomes after surgery including increased incidence of complications. High-flow nasal
cannula (HFNC) therapy can improve oxygenation of OSA patients by maintaining a certain
positive pressure in the nasopharyngeal cavity. Previous studies showed that, dexmedetomidine
supplemented analgesia can improve sleep quality and pain relief. The investigators
hypothesize that, for high-risk OSA patients following major non-cardiac surgery with HFNC
therapy, dexmedetomidine supplemented analgesia can improve sleep quality. The purpose of
this pilot randomized controlled trial is to investigate the impact of dexmedetomidine
supplemented analgesia on sleep quality in high-risk OSA patients after major non-cardiac
surgery.